12:00 AM
 | 
Oct 06, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ARQ 197: Phase II expanded

ArQule expanded enrollment in an ongoing open-label, U.S. Phase II trial after a partial objective response was observed among the 23 patients receiving 120 mg of oral ARQ 197 given twice daily....

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >